/foundation/biomed/b/weblog3/archive/2014/02/10/hepatera-a-skolkovo-resident-company-completes-enrollment-of-phase-iia-clinical-trial-of-myrcludex-b-a-novel-entry-inhibitor-for-treatment-of-chronic-hbv-infection.aspxA resident of the Russian Innovation Center Skolkovo Hepatera is developing an innovative drug candidate - Myrcludex B - for treatment of chronic viral hepatitis B and D in close cooperation with the German biotech company MYR GmbH, a portfolio company7.x Production